Related Experiment Video
Updated: May 28, 2026
A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma (DIPG)
Published on: March 7, 2017
Development of an Active Chimeric IL13Rα2 ADC for Diffuse Intrinsic Pontine Glioma
Xiaolei Lian1,2,3, Victoria J Allanson2, Samuel V Rasmussen2
1Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China.
Introduction:
Diffuse intrinsic pontine glioma (DIPG) is a rare pediatric brain tumor with a critical unmet need due to the lack of approved, curative interventions available. The interweaving of malignant cells with normal tissue makes surgical extraction essentially impossible, and radiation provides only transient benefit. The recent ONC201 FDA approval, however, suggests DIPG therapy is tractable. Having identified overexpression of IL13Rα2 in DIPG tumor tissue versus normal brain tissue, we investigated binding of commercially available IL13Rα2 monoclonal antibodies. The top candidate antibody was used to generate a chimeric antibody, to which we conjugated deruxtecan to create a preclinical therapeutic candidate.
Methods:
We validated the novel antibody-drug conjugate (ADC) in vitro, demonstrating dose-dependent, IL13Rα2 expression-dependent cell death. We further validated the novel ADC ex ovo in quail xenograft models of DIPG and in vivo in a mouse xenograft model.
Results:
The ADC showed tumor reduction in the ex ovo quail embryo model for both IL13Rα2-high and IL13Rα2-low DIPG cell models. A proof-of-concept in vivo mouse xenograft experiment demonstrated a reduction in tumor volume beyond antibody treatment alone.
Discussion:
The work here represents an important milestone in preclinical development of a novel deruxtecan-based ADC agent for an intractable pediatric brain cancer, concurrent with other ADC agents demonstrating real-world clinical efficacy and gaining approvals in multiple disease indications.
Insights
A new antibody-drug conjugate (ADC) targeting IL13Rα2 shows promise for treating diffuse intrinsic pontine glioma (DIPG), a rare pediatric brain cancer. This preclinical therapy demonstrated significant tumor reduction in both ex ovo and in vivo models.
Area of Science:
- Oncology
- Pediatric Neuro-oncology
- Drug Development
Background:
- Diffuse intrinsic pontine glioma (DIPG) is a rare pediatric brain tumor with limited treatment options.
- Surgical removal is impossible, and radiation offers only temporary relief.
- Recent FDA approvals suggest DIPG therapy is achievable.
Purpose of the Study:
- To develop a novel therapeutic agent for DIPG.
- To target IL13Rα2, which is overexpressed in DIPG tumors.
- To create a deruxtecan-conjugated antibody-drug conjugate (ADC).
Main Methods:
- Identified IL13Rα2 overexpression in DIPG tissues.
- Developed a chimeric antibody targeting IL13Rα2.
- Conjugated the antibody with deruxtecan to form an ADC.
- Validated the ADC in vitro and in quail and mouse xenograft models.
Main Results:
- The ADC demonstrated dose-dependent and IL13Rα2-dependent cell death in vitro.
- Tumor reduction was observed in ex ovo quail embryo models (IL13Rα2-high and low).
- In vivo mouse xenografts showed reduced tumor volume compared to antibody treatment alone.
Conclusions:
- This study presents a significant preclinical advancement for a novel deruxtecan-based ADC targeting DIPG.
- The findings support the potential of ADCs in treating intractable pediatric brain cancers.
- This work aligns with the growing clinical success of ADC agents in various indications.
